SCHEMBL14883371

SCHEMBL14883371

CN(C)c1ccc2nc(-c3csc4ccccc34)[nH]c(=O)c2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GUSB P08236 7/20 0.53
▸ KDM4E B2RXH2 3/20 0.53
▸ NPC1 O15118 2/20 0.53
▸ RAB9A P51151 2/20 0.53
▸ MAPT P10636 2/20 0.53
▸ PDE3B Q13370 1/20 0.44
▸ PDE3A Q14432 1/20 0.44
▸ IP6K1 Q92551 1/20 0.42
▸ HPGD P15428 3/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ KLF5 Q13887 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ TNKS O95271 1/20 0.40
▸ PARP1 P09874 1/20 0.40
▸ TNKS2 Q9H2K2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ APOBEC3G Q9HC16 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14883377 0.85 TNKS (0.50) GUSBKDM4ENPC1RAB9AMAPT
SCHEMBL15388637 0.82 AR (0.38) GUSBKDM4ENPC1RAB9AMAPT
SCHEMBL14876857 0.82 GUSB (0.58) GUSBKDM4ENPC1RAB9ATNKS
SCHEMBL14877275 0.81 GUSB (0.57) GUSBKDM4ENPC1RAB9AMAPT
SCHEMBL14876864 0.78 GUSB (0.54) GUSBKDM4ENPC1RAB9AMAPT
SCHEMBL14876949 0.77 KDM4E (0.53) GUSBKDM4EMAPTIP6K1HPGD
SCHEMBL14883379 0.76 KDM4E (0.52) GUSBKDM4EMAPTIP6K1HPGD
SCHEMBL14877218 0.75 FGFR1 (0.50) KDM4EMAPTHPGDMEN1KMT2A
SCHEMBL13590061 0.70 HSD17B10 (0.69) GUSBKDM4ENPC1RAB9AMAPT
SCHEMBL16007866 0.70 GUSB (1.00) GUSBKDM4ENPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9045437-B2 2-aryl-4-quinazolinones and their pharmaceutical compositions CHINA MEDICAL UNIVERSITY (TW) 2015-06-02 — — US disclosed
US-9045437-B2 2-aryl-4-quinazolinones and their pharmaceutical compositions CHINA MEDICAL UNIVERSITY (TW) 2015-06-02 — — US disclosed
US-9045437-B2 2-aryl-4-quinazolinones and their pharmaceutical compositions CHINA MEDICAL UNIVERSITY (TW) 2015-06-02 — — US disclosed
US-9006239-B2 2-aryl-4-quinazolinones and their pharmaceutical compositions CHINA MEDICAL UNIVERSITY (TW) 2015-04-14 — — US disclosed
US-9006239-B2 2-aryl-4-quinazolinones and their pharmaceutical compositions CHINA MEDICAL UNIVERSITY (TW) 2015-04-14 — — US disclosed
US-9006239-B2 2-aryl-4-quinazolinones and their pharmaceutical compositions CHINA MEDICAL UNIVERSITY (TW) 2015-04-14 — — US disclosed
US-20140018363-A1 2-ARYL-4-QUINAZOLINONES AND THEIR PHARMACEUTICAL COMPOSITIONS CHINA MEDICAL UNIVERSITY (TW) 2014-01-16 — — US disclosed
US-20140018363-A1 2-ARYL-4-QUINAZOLINONES AND THEIR PHARMACEUTICAL COMPOSITIONS CHINA MEDICAL UNIVERSITY (TW) 2014-01-16 — — US disclosed
US-20140018363-A1 2-ARYL-4-QUINAZOLINONES AND THEIR PHARMACEUTICAL COMPOSITIONS CHINA MEDICAL UNIVERSITY (TW) 2014-01-16 — — US disclosed
US-20130310376-A1 2-ARYL-4-QUINAZOLINONES AND THEIR PHARMACEUTICAL COMPOSITIONS CHINA MEDICAL UNIVERSITY (TW) 2013-11-21 — — US disclosed
US-20130310376-A1 2-ARYL-4-QUINAZOLINONES AND THEIR PHARMACEUTICAL COMPOSITIONS CHINA MEDICAL UNIVERSITY (TW) 2013-11-21 — — US disclosed
US-20130102602-A1 2-Aryl-4-Quinazolinones And Their Pharmaceutical Compositions CHINA MEDICAL UNIVERSITY (TW) 2013-04-25 — — US disclosed
US-20130102602-A1 2-Aryl-4-Quinazolinones And Their Pharmaceutical Compositions CHINA MEDICAL UNIVERSITY (TW) 2013-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130102602-A1 2-Aryl-4-Quinazolinones And Their Pharmaceutical Compositions AQP4, KRAS, RB1 GUSB 4070/4885KDM4E 1135/4885NPC1 765/4885
US-20130310376-A1 2-ARYL-4-QUINAZOLINONES AND THEIR PHARMACEUTICAL COMPOSITIONS CCNE2, NFE2, NR2E1 GUSB 4465/4885KDM4E 51/4885NPC1 1746/4885
US-20140018363-A1 2-ARYL-4-QUINAZOLINONES AND THEIR PHARMACEUTICAL COMPOSITIONS CCNE2, RB1, NR2E1 GUSB 4327/4885KDM4E 91/4885NPC1 1718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback